TY - JOUR AU - Camprubí-Rimblas, Marta AU - Tantinyà, Neus AU - Bringué, Josep AU - Guillamat-Prats, Raquel AU - Artigas, Antonio PY - 2018 TI - Anticoagulant therapy in acute respiratory distress syndrome JF - Annals of Translational Medicine; Vol 6, No 2 (January 25, 2018): Annals of Translational Medicine (Focus on “The 2nd International Symposium International Symposium on Acute Pulmonary Injury Translational Research organized by Hospital Universitario de Getafe, under the auspices of the: ‘INSPIRES®’.” ) Y2 - 2018 KW - N2 - Acute respiratory distress syndrome (ARDS) presents a complex pathophysiology characterized by pulmonary activated coagulation and reduced fibrinolysis. Despite advances in supportive care of this syndrome, morbidity and mortality remains high, leading to the need of novel therapies to combat this disease. Focus these therapies in the inhibition of ARDS development pathophysiology is essential. Beneficial effects of anticoagulants in ARDS have been proved in preclinical and clinical trials, thanks to its anticoagulant and anti-inflammatory properties. Moreover, local administration by nebulization in the alveolar compartment increases local efficacy and does not produce systemic bleeding. In this review the coagulation and fibrinolytic pathway and its pharmacological targets to treat ARDS are summarized. UR - https://atm.amegroups.org/article/view/18033